Contact : +1 (888) 308-1808

/

Percheron Announces Termination of Phase 2B Study of Avicursen for Duchenne

PPMD is disappointed to learn of Percheron Therapeutics’ recent decision to terminate the company’s ongoing Phase 2b randomized, placebo-controlled trial of avicursen (ATL1102) in non-ambulatory individuals living with Duchenne following the release of topline six-month results. Avicursen is an antisense oligonucleotide designed to reduce inflammation through inhibition of CD49d.

Percheron reported that the trial did not meet its primary endpoint, Performance of the Upper Limb 2.0 (PUL2.0) score, at week 25 compared to placebo. Additionally, while avicursen was found to be safe and well-tolerated, there were no statistically significant differences in efficacy on available secondary endpoints, nor was there demonstrated therapeutic benefit associated with treatment with avicursen.

According to Percheron, the company will examine this data, as well as further data expected in January 2025, to determine the best path forward for the avicursen program in the new year. PPMD is in communication with Percheron and will update the community as soon as additional information becomes available.

Read Percheron’s press release here.

The post Percheron Announces Termination of Phase 2B Study of Avicursen for Duchenne appeared first on Parent Project Muscular Dystrophy.

Leave a Reply

Your email address will not be published. Required fields are marked *